Vericel Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Vericel stock.
View analyst ratings for Vericel or view top-rated stocks.

Wall Street analysts have given Vericel a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Vericel wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Vericel is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Vericel.

Vericel Co. (NASDAQ:VCEL) released its quarterly earnings results on Tuesday, August, 3rd. The biotechnology company reported ($0.08) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.08). The biotechnology company had revenue of $39.52 million for the quarter, compared to the consensus estimate of $36.78 million. Vericel had a trailing twelve-month return on equity of 6.49% and a net margin of 5.78%. The business's revenue was up 97.5% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.18) earnings per share.
View Vericel's earnings history.

Vericel's stock was trading at $12.08 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VCEL shares have increased by 303.2% and is now trading at $48.71.
View which stocks have been most impacted by COVID-19.

Vericel issued an update on its FY 2021 earnings guidance on Wednesday, August, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $168 million-$171 million, compared to the consensus revenue estimate of $166.91 million.

6 brokerages have issued 12 month price objectives for Vericel's shares. Their forecasts range from $31.00 to $65.00. On average, they anticipate Vericel's stock price to reach $50.00 in the next twelve months. This suggests a possible upside of 2.6% from the stock's current price.
View analysts' price targets for Vericel or view top-rated stocks among Wall Street analysts.

6 employees have rated Vericel CEO Nick Colangelo on Glassdoor.com. Nick Colangelo has an approval rating of 49% among Vericel's employees. This puts Nick Colangelo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Vericel include CRISPR Therapeutics (CRSP), Neurocrine Biosciences (NBIX), Fate Therapeutics (FATE), Exelixis (EXEL), Beam Therapeutics (BEAM), Denali Therapeutics (DNLI), Vir Biotechnology (VIR), Twist Bioscience (TWST), Halozyme Therapeutics (HALO), Adaptive Biotechnologies (ADPT), Kodiak Sciences (KOD), Adagio Therapeutics (ADGI), Abcam (ABCM), Sana Biotechnology (SANA) and Recursion Pharmaceuticals (RXRX).
View all of VCEL's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Novavax (NVAX), Momo (MOMO), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Verastem (VSTM), Amarin (AMRN) and NVIDIA (NVDA).

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

Vericel's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (15.02%), Brown Capital Management LLC (9.84%), Vanguard Group Inc. (6.50%), State Street Corp (4.74%), Macquarie Group Ltd. (4.23%) and Federated Hermes Inc. (3.54%). Company insiders that own Vericel stock include Dominick Colangelo, Jonathan Mark Hopper, Michael Halpin, Paul K Wotton, Robert L Md Zerbe and Sean C Flynn.
View institutional ownership trends for Vericel.

VCEL stock was sold by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, BlackRock Inc., Invesco Ltd., State Street Corp, Next Century Growth Investors LLC, FMR LLC, Goldman Sachs Group Inc., and Lisanti Capital Growth LLC. Company insiders that have sold Vericel company stock in the last year include Dominick Colangelo, Jonathan Mark Hopper, Michael Halpin, Paul K Wotton, Robert L Md Zerbe, and Sean C Flynn.
View insider buying and selling activity for Vericel or view top insider-selling stocks.

VCEL stock was bought by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Conestoga Capital Advisors LLC, Fisher Asset Management LLC, Castleark Management LLC, JPMorgan Chase & Co., Dimensional Fund Advisors LP, Federated Hermes Inc., and First Trust Advisors LP.
View insider buying and selling activity for Vericel or or view top insider-buying stocks.

Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VCEL stock can currently be purchased for approximately $48.71.

Vericel has a market capitalization of $2.27 billion and generates $124.18 million in revenue each year. The biotechnology company earns $3.04 million in net income (profit) each year or $0.06 on an earnings per share basis.

Vericel employs 273 workers across the globe.

Vericel was founded in 1989.

The official website for Vericel is www.vcel.com.

Vericel is headquartered at 64 SIDNEY STREET, CAMBRIDGE MA, 02139.

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at (800) 556-0311 or via email at [email protected]el.com.